



## Nannochloropsis oculata

- Almega PL is a patent protected premium Long Chain Polyunsaturated Fatty Acid (LC-PUFA) Omega-3 from a vegetarian source.
- Almega PL is extracted from a natural strain of **microalgae** *Nannochloropsis oculata*, which is sustainably grown and naturally contains the highest possible EPA (25%) to DHA ratio. High EPA to DHA ratio has been shown to have a significant positive effect on cardiovascular health, inflammation and on mental health and function.
- Almega PL naturally contains other beneficial compounds including carotenoids, omega 7, coenzyme Q10 and chlorophyll all powerful phytonutrients providing a myriad of health benefits.

## How does it work?

- **Almega PL**, like krill oil, is bound with polar-lipids (phospholipids and glycolipids), providing the health benefits of EPA with enhanced absorption.
- Both animal studies and human clinical trials have shown **Almega PL** to have equivalent and higher bioavailability when directly compared with krill oil.
- Superior bioavailability of EPA on a gram-per-gram basis.
- Equivalent total Omega-3 absorption.

## **Potential Benefits**

EPA has positive health benefits for adults:

- Anti-inflammatory.
- Cardiovascular health and cholesterol reduction.
- Mental function and reduce symptoms of mild depression.
- Almega PL has improved bioavailability.
- No fishy burps.
- Sustainably grown and sourced.
- Suitable for vegetarians.

ADDRESS 21 Reaghs Farm Rd, Minto NSW, Australia 2566

**TEL** +61 2 8796 1400

MAIL info@Lipa.com.au

**ABN** 21 070 106 526

**WEB** www.Lipa.com.au

The above information is confidential, proprietary, and/or the intellectual property of Lipa Pharmaceuticals Australia Pty Ld. It may be neither transferred nor copied to any third party without the prior written consent of Lipa Pharmaceuticals or its subsidiary or affiliated companies. Disclaimer: Lipa Pharmaceuticals Australia Pty Ltd, nor its employees, accepts liability for any information provided that is not supported by The Therapeutic Goods Administration or other relevant regulatory agencies. While reasonable care has been taken to ensure that the information provided herein is accurate, this document is not an authoritative statement under the rules and regulations of the Therapeutic Goods Administration or other regulatory bodies.